Presentation of acute promyelocytic leukemia as granulocytic sarcoma.

abstract：BACKGROUND:Survival for childhood acute lymphoblastic leukemia (ALL) has reached 80-90%. Future improvement in treatment success will involve new technologies and medication, adding to the pressure on limited financial resources. Therefore a retrospective cost-effectiveness analysis of ALL treatment with chemotherapy o...

journal_title：Pediatric blood & cancer

authors： van Litsenburg RR,Uyl-de Groot CA,Raat H,Kaspers GJ,Gemke RJ

更新日期：2011-12-01 00:00:00

abstract：PURPOSE:Chemotherapy during radiation and/or bone-seeking radioisotope therapy (153-samarium; 1 mCi/kg) during radiation may improve osteosarcoma cancer control. PATIENTS AND METHODS:We analyzed our preliminary radiation experience in high-risk, metastatic, and/or recurrent patients during a consecutive period of 20 m...

journal_title：Pediatric blood & cancer

authors： Mahajan A,Woo SY,Kornguth DG,Hughes D,Huh W,Chang EL,Herzog CE,Pelloski CE,Anderson P

更新日期：2008-05-01 00:00:00

abstract：:Hepatoblastoma is a malignant pediatric liver tumor. The currently used diagnostic serum marker for hepatoblastoma, α-fetoprotein (AFP), is not always reliable in infants with hepatoblastoma, due to the physiologically elevated levels of AFP in this age group. In this report, we show that Delta-like 1 homolog (DLK1), ...

journal_title：Pediatric blood & cancer

authors： Falix FA,Aronson DC,Lamers WH,Hiralall JK,Seppen J

更新日期：2012-10-01 00:00:00

abstract：AIM:Osteopontin (OPN) has been investigated as a biomarker for cancer and nonmalignant diseases during the last decades. Data about OPN as a potential biomarker in childhood diseases are still sparse, and reference values are not available in children. We aimed to establish reference values for children from birth to y...

journal_title：Pediatric blood & cancer

authors： Nourkami-Tutdibi N,Graf N,Beier R,Zemlin M,Tutdibi E

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Alveolar soft-part sarcoma (ASPS), a rare vascular sarcoma with a clinically indolent course, frequently presents with metastases. Vascular endothelial growth factor (VEGF) is a promising therapeutic target. In a phase-II trial of the VEGF receptor inhibitor cediranib for adults with ASPS, the partial respon...

journal_title：Pediatric blood & cancer

authors： Cohen JW,Widemann BC,Derdak J,Dombi E,Goodwin A,Dompierre J,Onukwubiri U,Steinberg SM,O'Sullivan Coyne G,Kummar S,Chen AP,Glod J

更新日期：2019-12-01 00:00:00

abstract：BACKGROUND:ABT-751, an orally bioavailable sulfonamide, binds beta-tubulin to inhibit microtubule polymerization. We described response and event-free survival (EFS) in children with neuroblastoma and other solid tumors receiving ABT-751, assessed in vitro cytotoxicity of ABT-751 and evaluated the effect of ABT-751 on ...

journal_title：Pediatric blood & cancer

authors： Meany HJ,Sackett DL,Maris JM,Ward Y,Krivoshik A,Cohn SL,Steinberg SM,Balis FM,Fox E

更新日期：2010-01-01 00:00:00

abstract：:X-linked lymphoproliferative syndrome (XLP) is caused by mutations in SH2D1A, and is associated with overwhelming infectious mononucleosis, aplastic anemia, hypogammaglobulinemia, and B-cell lymphomas. However, the frequency of SH2D1A mutations in males who present with B NHL is unknown. Five cases of XLP were diagnos...

journal_title：Pediatric blood & cancer

authors： Sandlund JT,Shurtleff SA,Onciu M,Horwitz E,Leung W,Howard V,Rencher R,Conley ME

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Outcomes for childhood brain tumors are now associated with a five-year survival rate of 75%. Endocrine effects of brain tumors are common, occurring in 43% of patients by 10 years from tumor diagnosis. Optimal timing of screening for endocrinopathies remains undefined. We aim to identify incidence and timin...

journal_title：Pediatric blood & cancer

authors： Lawson SA,Horne VE,Golekoh MC,Hornung L,Burns KC,Fouladi M,Rose SR

更新日期：2019-05-01 00:00:00

abstract：:Treatment with the nucleoside analog cytarabine has been shown to mimic changes in gene expression associated with downregulation of the EWS-FLI1 oncogene in Ewing sarcoma cell lines, selectively inhibit their growth in vitro, and cause tumor regression in athymic nude mice. For this report cytarabine was studied in v...

journal_title：Pediatric blood & cancer

authors： Houghton PJ,Morton CL,Kang M,Reynolds CP,Billups CA,Favours E,Payne-Turner D,Tucker C,Smith MA

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

journal_title：Pediatric blood & cancer

authors： Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Chemotherapy-induced nausea and vomiting (CINV) negatively impacts patients' quality of life. The emetogenicity of high-dose methotrexate in children and adolescents with cancer is incompletely characterized. At our institution, a number of patients with acute lymphoblastic leukemia (ALL) have received aprep...

journal_title：Pediatric blood & cancer

authors： Felix-Ukwu F,Reichert K,Bernhardt MB,Schafer ES,Berger A

更新日期：2018-02-01 00:00:00

abstract：:In Wilms tumor (WT), mutations in the gene encoding p53, TP53, are correlated with anaplasia; however TP53 variants have not been studied in favorable histology (FH) WTs. A single nucleotide polymorphism of TP53 encoding either arginine or proline at codon 72 is suggested to alter in vitro p53 behavior. Therefore, we ...

journal_title：Pediatric blood & cancer

authors： Cost NG,Mitui M,Khokhar S,Wickiser JE,Baker LA,Rakheja D

更新日期：2012-08-01 00:00:00

abstract：:Malignant melanoma is rare in childhood and has never been reported to cause pancytopenia due to bone marrow metastases in a child. We report a 3-year-old boy with a large congenital melanocytic nevus who presented with bone pain and pancytopenia due to diffuse bone and bone marrow infiltration with metastatic melanom...

journal_title：Pediatric blood & cancer

authors： Spiller SE,Hawkins DS,Finn LS,Sze RW,Sybert V

更新日期：2005-07-01 00:00:00

abstract：PURPOSE:To evaluate the association of central nervous system (CNS) treatment intensity and the social functioning of children who have completed treatment for leukemia, lymphoma, and solid tumors outside the CNS. Furthermore, we expected that these associations would be moderated by child age at diagnosis and gender. ...

journal_title：Pediatric blood & cancer

authors： Vannatta K,Gerhardt CA,Wells RJ,Noll RB

更新日期：2007-10-15 00:00:00

abstract：BACKGROUND:For children with juvenile myelomonocytic leukemia (JMML) who undergo stem cell transplantation (SCT), the role of immunological interventions including withdrawal of immunosuppressive therapy (IST) and donor lymphocyte infusion (DLI) for treatment of disease recurrence remains uncertain. PROCEDURE:We analy...

journal_title：Pediatric blood & cancer

authors： Inagaki J,Fukano R,Nishikawa T,Nakashima K,Sawa D,Ito N,Okamura J

更新日期：2013-01-01 00:00:00

abstract：:Undifferentiated embryonal sarcoma of the liver (UESL) is a rare aggressive mesenchymal pediatric tumor. Previously, reported outcomes have been very poor. Here, we report a single-center experience of five patients with UESL treated with upfront gross total resection and adjuvant chemotherapy. We have a median follow...

journal_title：Pediatric blood & cancer

authors： Mathias MD,Ambati SR,Chou AJ,Slotkin EK,Wexler LH,Meyers PA,Magnan H

更新日期：2016-12-01 00:00:00

abstract：:We describe a child with dyserythropoietic anemia, thrombocytosis, functional platelet defect, and megakaryocyte dysplasia. We show that (i) this constellation of hematopoietic abnormalities was due to a germline mutation within the 5' untranslated region (5'UTR) of globin transcription factor 1 (GATA1); (ii) the muta...

journal_title：Pediatric blood & cancer

authors： Zucker J,Temm C,Czader M,Nalepa G

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Carboplatin is the most effective drug in retinoblastoma but systemic clearance is variable in young patients. While most regimens use a flat dose, individualized targeting may provide a more adjusted systemic exposure. PATIENTS AND METHODS:We compared carboplatin doses between two groups of children with r...

journal_title：Pediatric blood & cancer

authors： Allen S,Wilson MW,Watkins A,Billups C,Qaddoumi I,Haik BH,Rodriguez-Galindo C

更新日期：2010-07-15 00:00:00

abstract：BACKGROUND:Tumor cells frequently contaminate autologous stem cell products in a variety of malignancies, but their clinical significance remains controversial. We retrospectively monitored tumor contamination in stem cell harvests from patients with Ewing family of tumors (EFT) all harboring the specific translocation...

journal_title：Pediatric blood & cancer

authors： Yaniv I,Cohen IJ,Stein J,Zilberstein J,Liberzon E,Atlas O,Grunshpan A,Sverdlov Y,Ash S,Zaizov R,Avigad S

更新日期：2004-05-01 00:00:00

abstract：BACKGROUND:To investigate the incidence, clinical characteristics and survival of malignant tumours of the gastrointestinal tract in children in the West Midlands in Britain over a 44-year span time, to identify any change over this period and to compare the data with the world literature. PROCEDURE:Retrospective popu...

journal_title：Pediatric blood & cancer

authors： Hameed R,Parkes S,Davies P,Morland BJ

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:We report a 13-year-old male with Diamond Blackfan anemia and short stature. He had a normal biochemical response to growth hormone (GH) stimulation, but his bone age was delayed, his insulin-like growth factor 1 (IGF-1) was low, and he had a poor growth velocity. He was started on daily GH injections. METH...

journal_title：Pediatric blood & cancer

authors： Scott EG,Haider A,Hord J

更新日期：2004-10-01 00:00:00

abstract：:Survivors of childhood cancer are at risk for dental late effects. This systematic review summarizes associations between treatment exposures and dental late effects among survivors of childhood cancer. We included investigations with at least 20 study participants conducted for 2 or more years after completion of chi...

journal_title：Pediatric blood & cancer

authors： Gawade PL,Hudson MM,Kaste SC,Neglia JP,Constine LS,Robison LL,Ness KK

更新日期：2014-03-01 00:00:00

abstract：BACKGROUND:We assessed the safety and efficacy of ifosfamide and vinorelbine (IV) as a less toxic and effective reinduction regimen for pediatric patients with relapsed or refractory Hodgkin Lymphoma. PROCEDURE:This multi-center Children's Oncology Group phase II pilot study enrolled patients <30 years of age with bio...

journal_title：Pediatric blood & cancer

authors： Trippett TM,Schwartz CL,Guillerman RP,Gamis AS,Gardner S,Hogan S,London WB,Chen L,de Alarcon P

更新日期：2015-01-01 00:00:00

abstract：:Adherence is a critical consideration in ongoing efforts to improve outcomes among adolescents and young adults (AYAs) with cancer. In this narrative review, we embed existing conceptualizations of adherence within a developmental context to provide a novel vantage point from which to examine this important issue. App...

journal_title：Pediatric blood & cancer

authors： Vandermorris A,Sampson L,Korenblum C

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:A lack of access to methotrexate levels is common in low- and middle-income countries (LMIC), relevant for 80% of children with cancer worldwide. We evaluated whether high-dose methotrexate (HD-MTX) can be administered safely with extended hydration and leucovorin rescue, with monitoring of serum creatinine ...

journal_title：Pediatric blood & cancer

authors： Vaishnavi K,Bansal D,Trehan A,Jain R,Attri SV

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:The transition from the pediatric setting to adult care is a well-described period of morbidity and mortality for persons with sickle cell disease (SCD). We sought to measure the feasibility and effectiveness of providing skill-based educational handouts on improving self-management and transition readiness ...

journal_title：Pediatric blood & cancer

authors： Calhoun CL,Abel RA,Pham HA,Thompson S,King AA

更新日期：2019-07-01 00:00:00

abstract：:We report three cases of hemophagocytic lymphohistiocytosis (HLH) in infants within the first 6 weeks of life. Diagnosis of HLH was made early after symptoms started. All three cases were successfully treated with dexamethasone and none relapsed, indicating that not all cases of HLH in very young infants are familial....

journal_title：Pediatric blood & cancer

authors： Tanoshima R,Takahashi H,Hokosaki T,Yamaguchi K,Goto S,Kai S

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Treatment abandonment (TxA) is a primary cause of therapy failure in children with cancer in low-/middle-income countries. We explored the absence of social support network (SSN), among other predictive factors, and TxA in children with cancer in Cali, Colombia. PROCEDURE:In this prospective cohort study, w...

journal_title：Pediatric blood & cancer

authors： Ospina-Romero M,Portilla CA,Bravo LE,Ramirez O,VIGICANCER working group.

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms have been implicated in childhood acute lymphoblastic leukemia (ALL) risk, but previously published studies were inconsistent and recent meta-analyses were not adequate. PROCEDURES:In a meta-analysis of 21 publications with 4,706 cas...

journal_title：Pediatric blood & cancer

authors： Yan J,Yin M,Dreyer ZE,Scheurer ME,Kamdar K,Wei Q,Okcu MF

更新日期：2012-04-01 00:00:00

abstract：:We aimed to provide recommendations on the infusion duration of anthracycline chemotherapy agents in children with cancer. This study also serves as a practice example of the essential steps that need to be taken when using a previously published systematic review to develop a high-quality clinical practice guideline....

journal_title：Pediatric blood & cancer

authors： Loeffen EAH,van Dalen EC,Mulder RL,van de Wetering MD,Kremer LCM,Tissing WJE,Anthracycline Cardiotoxicity Working Group.

更新日期：2018-02-01 00:00:00